A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
University of California, Irvine
Memorial Sloan Kettering Cancer Center
Valo Therapeutics Oy
TCR2 Therapeutics
TCR2 Therapeutics
Memorial Sloan Kettering Cancer Center
Centre Hospitalier Universitaire Vaudois
ImmunoVaccine Technologies, Inc. (IMV Inc.)